[Form 4] SAB Biotherapeutics, Inc. Warrant Insider Trading Activity

Rhea-AI Filing Summary

Christoph Lawrence Bausch, Chief Operating Officer of SAB Biotherapeutics, Inc. (SABSW), was granted options to buy 600,000 shares of the company’s common stock at an exercise price of $2.17 per share. The option grant was reported with a transaction date of 08/26/2025 and an expiration date of 08/26/2035. The awards are governed by the Issuer’s 2021 Omnibus Equity Incentive Plan, as amended, but are conditioned on the Company receiving stockholder approval to amend the Plan to increase the number of shares available for issuance. The option shares vest over four years: one-quarter on March 1, 2026, and the remaining three-quarters monthly in 36 equal installments.

Positive

• 600,000 stock options granted to the Chief Operating Officer, indicating executive alignment with company performance objectives
• Clear vesting schedule: 1/4 vests on March 1, 2026, remainder vests monthly in 36 equal installments, providing retention incentives
• Defined exercise price and term: $2.17 exercise price with expiration on 08/26/2035

Negative

• Issuance is conditional on stockholder approval to amend the 2021 Omnibus Equity Incentive Plan to increase shares available for issuance
• Potential dilution implicit from a 600,000-share option award (requires monitoring of total share pool and approvals)

Insights

Compensation/Corporate Governance Specialist

TL;DR: A 10-year option grant of 600,000 shares at $2.17 was made to the COO, but issuance depends on shareholder approval to increase the plan pool.

The grant aligns long-term executive incentives by using time-based vesting over four years with a standard one-year cliff followed by monthly installments. The exercise price of $2.17 establishes the strike for potential future value realization. Materially, the awards are conditional on a stockholder vote to amend the Omnibus Plan to add share capacity, which is a gating factor for issuance. For governance review, note the size of the grant relative to existing plan capacity and the dependency on a shareholder approval process.

Securities/Equity Compensation Analyst

TL;DR: The Form 4 reports a large option award (600,000 shares) with standard vesting and a ten-year term; actual issuance requires plan amendment approval.

The option's ten-year term (08/26/2035) and defined vesting schedule are typical for executive grants. The filing clearly states the awards are subject to the Company obtaining stockholder approval to increase shares available under the 2021 Omnibus Equity Incentive Plan, making the grant contingent. From an investor-materiality perspective, the contingency and the magnitude of the grant are the primary facts to monitor in subsequent disclosures.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bausch Christoph Lawrence

(Last) (First) (Middle)

2100 E 54TH STREET NORTH

(Street)

SIOUX FALLS SD 57104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SAB Biotherapeutics, Inc. [ SABS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.17	08/26/2025		A		600,000(1)(2)		(3)	08/26/2035	Common Stock	600,000	$0	600,000	D

Explanation of Responses:

1. Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan").

2. The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder.

3. The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

	/s/ Christoph Bausch	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for SAB Biotherapeutics (SABSW)?

The reporting person is Christoph Lawrence Bausch, Chief Operating Officer, with the Form 4 signed on 08/28/2025.

What security was reported on the Form 4 for SAB Biotherapeutics?

A stock option (right to buy) to purchase 600,000 shares of common stock was reported.

What are the key economic terms of the option grant reported on 08/26/2025?

The option has an exercise price of $2.17 per share and an expiration date of 08/26/2035.

When do the option shares vest according to the Form 4?

Vesting is one-quarter on March 1, 2026 and the remaining three-quarters vest monthly in 36 equal installments thereafter.

Is the option grant immediately effective or conditional?

The awards are subject to the Company receiving stockholder approval to amend the 2021 Omnibus Equity Incentive Plan to increase shares available for issuance.